Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bausch + Lomb trumps failed Valeant bid for ISTA with $500m deal

This article was originally published in Scrip

Executive Summary

Eye care firm Bausch + Lomb has agreed to acquire ISTA Pharmaceuticals for $9.10 per share, or around $500 million in total, in cash. The deal represents a premium of 10% to ISTA's share price on 23 March, the last trading day before the transaction went public yesterday, and trumps the salvo of hostile offers from Valeant Pharmaceuticals, which rapidly escalated its bid from $6.50 per share last December through $7.50 to $8.50, but then withdrew from the running as its debt was downgraded by Moody's (scripintelligence.com, 31 January 2012).

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC016758

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel